[{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Affinivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-Valent Streptococcus Pneumoniae Vaccine","moa":"B-cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Astellas Pharma \/ Affinivax","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Affinivax"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Results from the trial presented no significant safety concerns. The neutralizing antibody titers 14 days after the second vaccination of DS-5670 have demonstrated acquirement of adequate immunity.

                          Product Name : DS-5670

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : DS-5670

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the terms of the parties’ new agreement, the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus ...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : $65.0 million

                          February 28, 2022

                          Lead Product(s) : 24-Valent Streptococcus Pneumoniae Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Affinivax

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : DS-5670, an mRNA vaccine against COVID-19 using a novel nucleic acid delivery technology in phase 1/2/3 study evaluate safety and efficacy in healthy Japanese adults who completed initial vaccination also induced neutralizing activities against Omicron v...

                          Product Name : DS-5670

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 31, 2022

                          Lead Product(s) : DS-5670

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).

                          Product Name : OPC-167832

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 08, 2021

                          Lead Product(s) : OPC-167832,Bedaquiline,Delamanid

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : $17.8 million

                          Deal Type : Funding

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The phase 1/2 trial is being conducted in Japan in a total of 152 healthy adults, including elderly individuals, to evaluate the safety and immunogenicity of the vaccine and thereby estimate the recommended dose of DS-5670.

                          Product Name : DS-5670

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 22, 2021

                          Lead Product(s) : DS-5670

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : First subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine...

                          Product Name : NVX-COV2373

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 24, 2021

                          Lead Product(s) : NVX-COV2373

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Moderna Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : First participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd. TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine cand...

                          Product Name : TAK-919

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 21, 2021

                          Lead Product(s) : TAK-919

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Moderna Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank